Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,608.50
Bid: 1,608.00
Ask: 1,609.00
Change: 10.50 (0.66%)
Spread: 1.00 (0.062%)
Open: 1,595.00
High: 1,626.00
Low: 1,588.00
Prev. Close: 1,598.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monday broker round-up UPDATE

Mon, 16th Jun 2014 09:51

Allocate Software: N+1 Singer upgrades to buy with a target price of 133p.Croda International: Numis cuts target price from 2575p to 2554p and maintains its hold recommendation.Diamondcorp: Northland Capital shifts target price from 9.9p to 11p and keeps a buy recommendation.Fenner: Credit Suisse reduces target price from 490p to 405p and stays with its outperform rating.GlaxoSmithKline: Societe Generale ups target price from 2075p to 2100p and retains a buy recommendation.Glencore Xstrata: Investec moves target price from 302p to 319p upgrading from reduce to hold.Halma: Credit Suisse ups target price from 620p to 665p and reiterates an outperform rating.IG Group: Canaccord Genuity cuts target price from 711p to 659p, while staying with its buy recommendation.Laird: Credit Suisse raises target price from 215p to 270p, while leaving its underperform rating unchanged.Lamprell: Investec shifts target price from 150p to 155p and reiterates a hold recommendation.Morgan Advanced Materials: Credit Suisse ups target price from 270p to 310p and maintains an underperform rating.Oxford Instruments: N+1 Singer ups target price to 1445p and maintains its hold recommendation.Petra Diamonds: Numis moves target price from 200p to 220p keeping its buy recommendation.Reckitt Benckiser: Exane raises target price from 4500p to 4900p, while staying with its underperform rating.Rio Tinto: Investec reduces target price from 3624p to 3128p downgrading from buy to hold. Exane reduces target price from 4070p to 3800p and stays with its outperform rating.Rolls-Royce Group: Societe Generale reduces target price from 1070p to 950p downgrading from hold to sell.Rotork: Credit Suisse increases target price from 2450p to 2600p and stays with its neutral rating.Senior: Credit Suisse moves target price from 315p to 335p and keeps an outperform rating.Science in Sport: Sanlam Securities initiates with a target price of 83p and a buy recommendation.Zambeef: Panmure Gordon reinstates with a target price of 30p and a buy recommendation.
More News
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.